Medicenna Therapeutics Corp. (TSE:MDNA) Senior Officer David Hyman Purchases 20,000 Shares of Stock

Medicenna Therapeutics Corp. (TSE:MDNA) Senior Officer David Hyman purchased 20,000 shares of Medicenna Therapeutics stock in a transaction dated Thursday, January 9th. The shares were bought at an average price of C$1.45 per share, with a total value of C$29,000.00.

Medicenna Therapeutics Stock Performance

TSE MDNA opened at C$1.37 on Friday. The business has a 50 day moving average price of C$1.80 and a 200 day moving average price of C$2.01. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.51 and a quick ratio of 4.65. The company has a market capitalization of C$104.71 million, a P/E ratio of -3.61 and a beta of 1.21. Medicenna Therapeutics Corp. has a 1-year low of C$0.40 and a 1-year high of C$2.98.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.